表紙
市場調查報告書

B型流感病毒感染:開發中產品分析

Influenzavirus B Infections - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 484630
出版日期 內容資訊 英文 147 Pages
訂單完成後即時交付
價格
Back to Top
B型流感病毒感染:開發中產品分析 Influenzavirus B Infections - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 147 Pages
簡介

B型流感是零星發生並具有發射性傳染趨勢的流感病毒亞型。症候有鼻涕,咽喉炎,肌肉痛,不舒服,淚眼,身體疼痛,食慾衰退,衰弱等。治療有使用處方抗病毒藥物,止痛藥,退燒藥等。

本報告提供全球各國治療B型流感病毒感染所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介+

  • 調查範圍

B型流感病毒感染;概要

B型流感病毒感染 - 治療藥的開發

  • 開發中產品 概要
  • 開發中產品:各企業
  • 開發中產品:各大學/研究機關
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc
  • Altravax Inc
  • Amarillo Biosciences Inc
  • Aphios Corp
  • BioClonetics Immunotherapeutics Inc
  • ContraFect Corp
  • 第一三共
  • GlaxoSmithKline Plc
  • Green Cross Corp
  • Ilyang Pharmaceutical Co Ltd
  • Kineta Inc
  • Medicago Inc
  • MedImmune LLC
  • Mucosis BV
  • Novavax Inc
  • Protein Sciences Corp
  • Romark Laboratories LC
  • Sanofi Pasteur SA
  • 鹽野義製藥
  • SK Chemicals Co Ltd
  • 富山化學工業
  • TSRL Inc
  • Vaxart Inc
  • Vectura Group Plc
  • Zydus Cadila Healthcare Ltd

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11545IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2019, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.

Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 10, 7, 3, 17 and 5 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 4, 1 and 1 molecules, respectively.

Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenzavirus B Infections - Overview
  • Influenzavirus B Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Influenzavirus B Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Influenzavirus B Infections - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Abhelix LLC
    • Adimmune Corp
    • Allergy Therapeutics Plc
    • Ansun Biopharma Inc
    • Aphios Corp
    • AstraZeneca Plc
    • AusBio Ltd
    • Biotron Ltd
    • BlueWillow Biologics Inc
    • Cidara Therapeutics Inc
    • Cocrystal Pharma Inc
    • ContraFect Corp
    • Daiichi Sankyo Co Ltd
    • e-Therapeutics Plc
    • Evotec SE
    • Evrys Bio
    • Fujifilm Toyama Chemical Co Ltd
    • GC Pharma
    • Imutex Ltd
    • Inovio Pharmaceuticals Inc
    • iQur Ltd
    • Johnson & Johnson
    • Medicago Inc
    • Novavax Inc
    • Osivax SAS
    • Park Active Molecules
    • Romark Laboratories LC
    • Sanofi Pasteur SA
    • Sciogen Inc
    • Seqirus Ltd
    • Serum Institute of India Ltd
    • Shanghai Institute of Biological Products Co Ltd
    • Shionogi & Co Ltd
    • Sinovac Biotech Ltd
    • Therapeutic Systems Research Laboratories Inc
    • UMN Pharma Inc
    • Vacthera BioTech GmbH
    • Vaxart Inc
    • Ventaleon GmbH
    • Viramatix Sdn Bhd
    • Wuhan Institute of Biological Products Co Ltd
  • Influenzavirus B Infections - Drug Profiles
    • Afluria Quadrivalent - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APP-0205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APP-309 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • baloxavir marboxil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-12G6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-403 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DAS-181 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETS-5200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • favipiravir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Flu-v - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fluad (Quadrivalent) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fludase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fluzone QIV HD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-3106A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Influenzavirus B Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Inhibit Hemagglutinin for Influenza Virus A and B Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza (quadrivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [serotypes A, B] (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A + B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/ Yamagata + B/ Victoria] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1+A/H3N2+B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • laninamivir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MD-2009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDG-2271 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Influenza B Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A and B Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Influenza B Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-1008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitazoxanide CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAM-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block M2 Proton Channel for Influenzavirus A and B Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Sirtuin for Influenza - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PA for Influenzavirus A and B Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UMN-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VMTX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VR-736 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTH-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VXABYW-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zanamivir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Influenzavirus B Infections - Dormant Projects
  • Influenzavirus B Infections - Discontinued Products
  • Influenzavirus B Infections - Product Development Milestones
    • Featured News & Press Releases
      • Nov 04, 2019: Sanofi: FDA approves Fluzone High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
      • Oct 03, 2019: Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences
      • Aug 29, 2019: Shionogi announces XOFLUZA tablets 20mg for the treatment of Influenza Types A and B in patients 12 years of age and older approved in Taiwan.
      • Aug 21, 2019: Cidara Therapeutics to present data from its Cloudbreak antiviral program at the Options X for the Control of Influenza conference
      • Jun 05, 2019: Cidara Therapeutics to present new data on CB-012 at ASM Microbe 2019
      • Apr 15, 2019: Cidara Therapeutics selects first clinical development candidate from its Cloudbreak Influenza (Antiviral) Program
      • Jan 27, 2019: Flu viruses resistant to new drug Xofluza uncovered in Japan
      • Jan 03, 2019: Novavax announces positive phase 2 NanoFlu results in older adults
      • Oct 24, 2018: Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
      • Sep 27, 2018: Shionogi to present data on Baloxavir Marboxil at IDWeek 2018
      • Sep 06, 2018: Baloxavir Marboxil phase II and III studies for the treatment of Influenza published in the New England Journal of Medicine
      • Jul 30, 2018: Sanofi ships first flu vaccines for 2018-2019 season
      • Jul 16, 2018: Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu
      • Jul 02, 2018: Shionogi Filed for the New Drug Application of Baloxavir Marboxil in Taiwan for the Treatment of Influenza
      • Jun 26, 2018: Roche's influenza drug secures FDA priority review status
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Influenzavirus B Infections, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 5: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 6: Products under Development by Companies, H2 2019
  • Table 7: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 8: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 9: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 10: Products under Development by Universities/Institutes, H2 2019
  • Table 11: Number of Products by Stage and Target, H2 2019
  • Table 12: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 13: Number of Products by Stage and Route of Administration, H2 2019
  • Table 14: Number of Products by Stage and Molecule Type, H2 2019
  • Table 15: Influenzavirus B Infections - Pipeline by AbbVie Inc, H2 2019
  • Table 16: Influenzavirus B Infections - Pipeline by Abhelix LLC, H2 2019
  • Table 17: Influenzavirus B Infections - Pipeline by Adimmune Corp, H2 2019
  • Table 18: Influenzavirus B Infections - Pipeline by Allergy Therapeutics Plc, H2 2019
  • Table 19: Influenzavirus B Infections - Pipeline by Ansun Biopharma Inc, H2 2019
  • Table 20: Influenzavirus B Infections - Pipeline by Aphios Corp, H2 2019
  • Table 21: Influenzavirus B Infections - Pipeline by AstraZeneca Plc, H2 2019
  • Table 22: Influenzavirus B Infections - Pipeline by AusBio Ltd, H2 2019
  • Table 23: Influenzavirus B Infections - Pipeline by Biotron Ltd, H2 2019
  • Table 24: Influenzavirus B Infections - Pipeline by BlueWillow Biologics Inc, H2 2019
  • Table 25: Influenzavirus B Infections - Pipeline by Cidara Therapeutics Inc, H2 2019
  • Table 26: Influenzavirus B Infections - Pipeline by Cocrystal Pharma Inc, H2 2019
  • Table 27: Influenzavirus B Infections - Pipeline by ContraFect Corp, H2 2019
  • Table 28: Influenzavirus B Infections - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Table 29: Influenzavirus B Infections - Pipeline by e-Therapeutics Plc, H2 2019
  • Table 30: Influenzavirus B Infections - Pipeline by Evotec SE, H2 2019
  • Table 31: Influenzavirus B Infections - Pipeline by Evrys Bio, H2 2019
  • Table 32: Influenzavirus B Infections - Pipeline by Fujifilm Toyama Chemical Co Ltd, H2 2019
  • Table 33: Influenzavirus B Infections - Pipeline by GC Pharma, H2 2019
  • Table 34: Influenzavirus B Infections - Pipeline by Imutex Ltd, H2 2019
  • Table 35: Influenzavirus B Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
  • Table 36: Influenzavirus B Infections - Pipeline by iQur Ltd, H2 2019
  • Table 37: Influenzavirus B Infections - Pipeline by Johnson & Johnson, H2 2019
  • Table 38: Influenzavirus B Infections - Pipeline by Medicago Inc, H2 2019
  • Table 39: Influenzavirus B Infections - Pipeline by Novavax Inc, H2 2019
  • Table 40: Influenzavirus B Infections - Pipeline by Osivax SAS, H2 2019
  • Table 41: Influenzavirus B Infections - Pipeline by Park Active Molecules, H2 2019
  • Table 42: Influenzavirus B Infections - Pipeline by Romark Laboratories LC, H2 2019
  • Table 43: Influenzavirus B Infections - Pipeline by Sanofi Pasteur SA, H2 2019
  • Table 44: Influenzavirus B Infections - Pipeline by Sciogen Inc, H2 2019
  • Table 45: Influenzavirus B Infections - Pipeline by Seqirus Ltd, H2 2019
  • Table 46: Influenzavirus B Infections - Pipeline by Serum Institute of India Ltd, H2 2019
  • Table 47: Influenzavirus B Infections - Pipeline by Shanghai Institute of Biological Products Co Ltd, H2 2019
  • Table 48: Influenzavirus B Infections - Pipeline by Shionogi & Co Ltd, H2 2019
  • Table 49: Influenzavirus B Infections - Pipeline by Sinovac Biotech Ltd, H2 2019
  • Table 50: Influenzavirus B Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, H2 2019
  • Table 51: Influenzavirus B Infections - Pipeline by UMN Pharma Inc, H2 2019
  • Table 52: Influenzavirus B Infections - Pipeline by Vacthera BioTech GmbH, H2 2019
  • Table 53: Influenzavirus B Infections - Pipeline by Vaxart Inc, H2 2019
  • Table 54: Influenzavirus B Infections - Pipeline by Ventaleon GmbH, H2 2019
  • Table 55: Influenzavirus B Infections - Pipeline by Viramatix Sdn Bhd, H2 2019
  • Table 56: Influenzavirus B Infections - Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2019
  • Table 57: Influenzavirus B Infections - Dormant Projects, H2 2019
  • Table 58: Influenzavirus B Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Table 59: Influenzavirus B Infections - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Influenzavirus B Infections, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top